Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Animal-health turnaround with Q1 2026 revenue up 15% YoY and guidance raised for revenue, adjusted EBITDA, adjusted EPS, innovation revenue, and net leverage; recent product launches/approvals and unusual options activity support near-term attention into 2026-08-05 earnings.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin recovery ⢠Positive cash flow ⢠Elevated leverage ELAN's improving quarterly margins and positive free cash flow support recovery potential, but high leverage, weak interest coverage, and intangible-heavy assets warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Oversold momentum ⢠Unconfirmed reversal Support Level: $22.15â$22.40 Resistance Level: $23.15â$23.17 ELAN remains in a last-month downtrend, with oversold RSI hinting at a possible bounce from $22.40â$22.15 support, but a bullish reversal requires reclaiming $23.15â$23.17.
Sentiment & News
Key News Insights: ⢠Pet Health Momentum ⢠Biologics Capacity Expansion ⢠Supply Constraint Risk Elanco's accelerating pet-health innovation, expanded biologics capacity, and supportive investor activity signal improving growth momentum, though Befrena supply constraints remain a near-term watchpoint.
AI Summary
ELAN is evolving into an innovation-led growth and margin-expansion story as Zenrelia and Credelio Quattro drive operating leverage and deleveraging, but investors should require sustained launch adoption, free-cash-flow conversion, and progress toward GAAP profitability given ~3x leverage and thin interest coverage.
Description
Elanco Animal Health Inc. develops, manufactures and markets pharmaceuticals, vaccines and nutritional health products for companion animals and food-producing species, including treatments for parasites, infectious disease and common chronic conditions. The company distributes through third-party distributors, veterinarians and farm producers across beef, dairy, pork, poultry and aquaculture markets; it was founded in 1954 and is headquartered in Greenfield, Indiana.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 21 | Jul 28 | ELAN | Elanco Animal Health Incorporated | Animal-health turnaround with Q1 2026 revenue up 15% YoY and guidance raised for revenue, adjusted EBITDA, adjusted EPS, innovation revenue, and net leverage; recent product launches/approvals and unusual options activity support near-term attention into 2026-08-05 earnings. | Closed | +0.2% |
| Jun 24 | Jul 1 | ELAN | Elanco Animal Health Incorporated | Multiple fresh animal-health catalysts: on 2026-05-06 Elanco raised full-year 2026 revenue, adjusted EBITDA, and adjusted EPS guidance; on 2026-06-15 USDA approved TruCan Ultra Lyme-L4 with shipping expected within 30 days; Q1 2026 margins and profitability improved, supporting a constructive short-term setup. | Closed | +0.5% |
| Jun 12 | Jun 19 | ELAN | Elanco Animal Health Incorporated | Animal-health guidance raise with product catalysts: Q1 2026 revenue grew 15% YoY to $1.371B, management raised 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and innovation revenue, while new launches such as Advantage Collar for Dogs and Befrena support near-term sentiment. Stock is up about 12% over 21 trading days. | Closed | +0.2% |
| Jun 5 | Jun 12 | ELAN | Elanco Animal Health Incorporated | Animal-health recovery with concrete catalysts: Q1 2026 revenue grew 15% YoY to $1.371B and management raised full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and year-end leverage. New products including Befrena and Advantage Collar plus the New World screwworm backdrop add timely sector support. | Closed | +2.3% |